Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479222 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479388 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL37559 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL672371 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL671456 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619726 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619498 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479563 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479610 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL1576782 | 0.96 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458092-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4704819-A1 | NANOPARTICLE COMPOSITION FOR OXYGEN DELIVERY | Swaza Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024227100-A1 | NANOPARTICLE COMPOSITION FOR OXYGEN DELIVERY | SWAZA INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024216162-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2008051818-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007065017-A2 | OLIGONUCLEOTIDE CATIONIC LIPOSOMAL DELIVERY SYSTEM | PRONAI THERAPEUTICS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1474107-A2 | EFFICIENT LIPOSOMAL ENCAPSULATION UNDER MILD CONDITIONS | Elan Pharmaceuticals, Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1471885-A2 | EFFICIENT LIPOSOMAL ENCAPSULATION | Elan Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003059280-A2 | EFFICIENT LIPOSOMAL ENCAPSULATION | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059279-A2 | EFFICIENT LIPOSOMAL ENCAPSULATION UNDER MILD CONDITIONS | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003057190-A1 | EFFICIENT NUCLEIC ACID ENCAPSULATION INTO MEDIUM SIZED LIPOSOMES | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003057189-A1 | EFFICIENT LIPOSOMAL ENCAPSULATION UNDER MILD CONDITIONS | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |